In 2008, the 13 companies on the list accounted for 34 per cent of the overall m-cap.
The deal had separately come under scanner of the market regulator Sebi for alleged insider trading violations and the present 'no-objection' from the exchanges.
A global policy would reward firms which strive for higher quality.
Sun Pharma's Dilip Shanghvi is India's richest person.
Ranbaxy was asked to sell all products containing Leuprorelin which are marketed and supplied under brand name Eligard.
The combined market valuation of top six Sensex companies surged by Rs 26,346 crore last week, with Reliance Industries and HDFC contributing the most to the gains.
Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.
4 Ranbaxy facilities in India have been barred from exporting to US.
The Gurgaon-headquartered drug maker, set to be acquired by another leading domestic company, Sun Pharmaceutical Industries, reported a consolidated net loss of Rs 186 crore for the quarter ended June.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
The FDA has stepped up its efforts to ensure drug safety in recent months.
In 2014, Sun Pharma agreed to buy Ranbaxy -- which was then controlled by Daiichi.
Hero MotoCorp's promoter Pawan Munjal emerged as the highest paid director.
The BSE Mid-cap index gained 1.1% while the Small-cap index surged 1.3%, outperforming the benchmark indices
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
On January 31, the US Federal Trade Commission cleared the merger.
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
Ranbaxy Laboratories on Wednesday reported widening of its consolidated net loss to Rs 1,029.72 crore (Rs 10.29 billion) for the third quarter ended December 31, 2014
Launches cloud-based version of solution to target mid-size clients in life sciences.
Analysts say those taking exposure through stocks could look at firms focused on domestic business
It goes without saying that the best performers are in the private sector, says TN Ninan.
A source said the competition watchdog would by next month suggest 'structural remedies' that included selling key drug segments as conditions for clearing the country's largest pharmaceutical industry merger.
The Nifty50 slipped 33 points to close the session at 8,509 after hitting an intra-day high of 8,587.
Currently, only three have completed more than six months of operation in the space - Fino Payments Bank, Airtel Payments Bank and Paytm
The turmoil on the Street and a continued fall of the rupee may affect growth stocks, pushing equity investors back to the relative safety of defensive counters, or forcing them to flee markets, or both.
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
The US Food and Drug Administration (FDA) says it does not follow an India agenda.
The year saw 30 QIP deals raising over $5 billion and 35 IPOs.
Top losers are Sun Pharma, Bajaj Auto, L&T, ITC, Hero Moto.
Some Indian generic drugmakers are, however, uncertain about the pace of approvals in the near future.
In August, RBI allowed 11 business houses to start a payments bank.
In 2013, Daiichi had launched the arbitration proceedings in Singapore.
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
Of the 23 Indian billionaires mentioned in the Bloomberg Billionaires Index, only one saw a reduction in net worth, with the companies owned by most of them outperforming the Nifty 50 index by a big margin.
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.
Combined net profit estimated to grow 14.6% year-on-year, against a 5.7% decline in the Dec 2015 quarter
Additional levy to eat into Rs 6,000-crore income of top promoters
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances